常染色体显性多囊肾病:2025核心教程
常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾衰竭病因。本核心教程讨论了ADPKD肾脏及肾外表现(包括急慢性疼痛、囊肿感染、多囊肝和颅内动脉瘤)的诊断与管理,并涵盖高血压管理及女性健康与妊娠管理,内容与近期KDIGO临床实践指南一致。
要点
- 总肾脏体积、肾功能与已知基因突变联合预测进展至肾衰竭的风险,据此识别推荐接受疾病修饰治疗的患者。
- 目前美国FDA批准一种延缓ADPKD进展的疗法,即V2受体拮抗剂托伐普坦。
- 本核心教程涵盖ADPKD肾脏及肾外表现(含急慢性疼痛、囊肿感染、多囊肝、颅内动脉瘤)及高血压、女性健康与妊娠管理。
核心结论
- ADPKD是最常见的遗传性肾衰竭病因,科学进展改善了其诊断、预后及肾脏与肾外表现的管理。
研究设计与样本
- 核心教程综述,内容与近期发表的KDIGO关于ADPKD评估、管理与治疗的临床实践指南相一致。
主要发现
- 总肾脏体积、肾功能与已知基因突变联合可预测进展至肾衰竭的风险。
- 目前美国FDA批准一种延缓ADPKD进展的疗法,即V2受体拮抗剂托伐普坦。
- 其他疗法正在积极研究中。
临床怎么用
- 通过总肾脏体积、肾功能与已知基因突变联合评估进展至肾衰竭的风险,识别推荐接受疾病修饰治疗的患者。
- 目前美国FDA批准用于延缓ADPKD进展的疗法为V2受体拮抗剂托伐普坦。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause of kidney failure. Scientific advances have improved the approach to diagnosis, prognosis, and management of renal and extrarenal manifestations. The combination of total kidney volume, kidney function, and the genetic mutation (if known), predicts risk for progression to kidney failure, thereby identifying patients in whom disease modifying therapy is recommended. Currently there is one therapy approved by the US Food and Drug Administration (FDA) for slowing ADPKD progression, the V2 receptor antagonist, tolvaptan. Other therapies are under active investigation for ADPKD. This Core Curriculum discusses diagnosis and management of the renal and extrarenal manifestations seen in ADPKD including acute and chronic pain and cyst infection and polycystic liver disease and intracranial aneurysm. Management of hypertension and women's health and pregnancy management in ADPKD are covered. This review was aligned with the findings of the recently published Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for the Evaluation, Management, and Treatment of ADPKD.
引用
- Gordon CE, Garimella PS, Perrone RD, et al. Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2025. Am J Kidney Dis. 2025. PMID: 40844441. doi:10.1053/j.ajkd.2025.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。